DE60303296T2 - Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten - Google Patents

Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten Download PDF

Info

Publication number
DE60303296T2
DE60303296T2 DE60303296T DE60303296T DE60303296T2 DE 60303296 T2 DE60303296 T2 DE 60303296T2 DE 60303296 T DE60303296 T DE 60303296T DE 60303296 T DE60303296 T DE 60303296T DE 60303296 T2 DE60303296 T2 DE 60303296T2
Authority
DE
Germany
Prior art keywords
cells
ethylphenyl
methoxyphenyl
cell
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60303296T
Other languages
German (de)
English (en)
Other versions
DE60303296D1 (de
Inventor
L. Sigma-Tau Ind. Farm. Riunite S.P. Battistini
G. Sigma-Tau Ind. Farm. Riunite S.P. Borsellino
R. Sigma-Tau Ind. Farm. Riunite S.P. De Santis
P. Sigma-Tau Ind. Farm. Riunite S.P. Carminati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60303296D1 publication Critical patent/DE60303296D1/de
Publication of DE60303296T2 publication Critical patent/DE60303296T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60303296T 2002-05-03 2003-04-15 Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten Expired - Fee Related DE60303296T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/137,699 US6797722B2 (en) 2002-05-03 2002-05-03 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
US137699 2002-05-03
PCT/IT2003/000237 WO2003092681A1 (en) 2002-05-03 2003-04-15 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
DE60303296D1 DE60303296D1 (de) 2006-04-06
DE60303296T2 true DE60303296T2 (de) 2006-08-17

Family

ID=29269138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60303296T Expired - Fee Related DE60303296T2 (de) 2002-05-03 2003-04-15 Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten

Country Status (15)

Country Link
US (2) US6797722B2 (https=)
EP (1) EP1501505B1 (https=)
JP (1) JP2005529904A (https=)
KR (1) KR20040111491A (https=)
AT (1) ATE315935T1 (https=)
AU (1) AU2003224453A1 (https=)
CA (1) CA2483904A1 (https=)
DE (1) DE60303296T2 (https=)
DK (1) DK1501505T3 (https=)
ES (1) ES2257666T3 (https=)
MX (1) MXPA04010785A (https=)
PL (1) PL374252A1 (https=)
PT (1) PT1501505E (https=)
TW (1) TWI284532B (https=)
WO (1) WO2003092681A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
DE3808283A1 (de) * 1988-03-12 1989-09-21 Boehringer Ingelheim Kg Neue 3,4,5-substituierte 4h-1,2,4-triazole, ihre herstellung und verwendung
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
ATE298740T1 (de) * 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
IT1292092B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
EP1099695A1 (en) * 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
PL374252A1 (en) 2005-10-03
EP1501505B1 (en) 2006-01-18
EP1501505A1 (en) 2005-02-02
JP2005529904A (ja) 2005-10-06
CA2483904A1 (en) 2003-11-13
ES2257666T3 (es) 2006-08-01
PT1501505E (pt) 2006-05-31
US20050026980A1 (en) 2005-02-03
MXPA04010785A (es) 2005-03-07
DK1501505T3 (da) 2006-05-22
US6797722B2 (en) 2004-09-28
AU2003224453A1 (en) 2003-11-17
ATE315935T1 (de) 2006-02-15
TW200418464A (en) 2004-10-01
DE60303296D1 (de) 2006-04-06
WO2003092681A1 (en) 2003-11-13
KR20040111491A (ko) 2004-12-31
TWI284532B (en) 2007-08-01
US20030207931A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
Kelley et al. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis.
DE60035057T2 (de) CD40 Antagonist zur Behandlung von Psoriasis
DE69207847T2 (de) Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen
DE69533331T2 (de) Liganden zur induktion der antigen-spezifischen apoptose in t-zellen
DE69127470T2 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
DE69634782T2 (de) Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12
DE69630479T2 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
DE3433339C2 (de) Zellmembran-Proteine enthaltende Arzneimittel zur Behandlung von Autoimmunkrankheiten und Verfahren zu ihrer Herstellung
DE69907945T2 (de) Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose
DE69425246T2 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
DE10261223A1 (de) Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
EP0474712B1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE69029134T2 (de) Monoklonale antikörper zur induzierung von toleranz
DE69821506T2 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
DE60303296T2 (de) Verwendung von (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten
EP2481757A1 (de) Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
EP0756605B1 (de) Peptide als therapeutikum für autoimmunerkrankungen
DE69533311T2 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE102004042894A1 (de) Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen
DE60024967T2 (de) Chaperonin 10 und beta-interferon therapie für multiple sklerose
EP1446139A2 (de) Pharmazeutische zusammensetzung enthaltend sfcyr llb oder sfcyr iii
DE69728654T2 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
EP1381387B1 (de) Verwendung von stimulierten mononuklearen zellen des peripheren blutes zur behandlung von krebserkrankungen
DE69903964T2 (de) Chemokin rezeptor antagonist und cyclosporin in kombinationstherapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee